| Yazarlar |
Oguz Karabay
|
|
Ayse Batirel
|
|
Ilker Inanc Balkan
|
|
Canan Agalar
|
|
Serife Akalin
|
|
Ozlem Alici
|
|
Emine Alp
|
|
F. Aybala Alta
|
|
N. Altin
|
|
Ferhat Arslan
|
|
Turan Aslan
|
|
Nural Bekiroglu
|
|
Salim Cesur
|
|
Aygul Dogan Celik
|
|
Mustafa Dogan
|
|
Bulent Durdu
|
|
Fazilet Duygu
|
|
Aynur Engin
|
|
Derya Ozturk Engin
|
|
Ibak Gonen
|
|
Ertugrul Guclui
|
|
Tumer Guven
|
|
Cigdem Ataman Hatipoglu
|
|
Salih Hosoglu
|
Prof. Dr. Mustafa Kasım KARAHOCAGİL
Kırşehir Ahi Evran Üniversitesi |
|
Aysegul Ulu Kilic
|
|
Bahar Ormen
|
|
Davut Ozdemir
|
|
Serdal Ozer
|
|
Nefise Oztoprak
|
|
Nurbanu Sezak
|
|
Vedat Turhan
|
|
N. Turker
|
|
Hava Yilmaz
|
| Özet |
| Objective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (452%) cases were male and the mean age was 602 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38 degrees C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (542%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33 3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality. |
| Anahtar Kelimeler |
| Acinetobacter baumannii | Bacteremia | Colistin | Monotherapy | Multi-drug resistant | Sepsis |
| Makale Türü | Özgün Makale |
| Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
| Dergi Adı | ACTA MEDICA MEDITERRANEA |
| Dergi ISSN | 0393-6384 |
| Dergi Grubu | Q4 |
| Makale Dili | İngilizce |
| Basım Tarihi | 01-2014 |
| Cilt No | 30 |
| Sayı | 5 |
| Sayfalar | 1137 / 1143 |
